HGP 1909
Alternative Names: HGP-1909Latest Information Update: 28 Dec 2023
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Hypercholesterolaemia(In volunteers) in South Korea (PO)
- 28 Aug 2023 No recent reports of development identified for clinical-Phase-Unknown development in Hypercholesterolaemia in South Korea (PO)
- 14 Jul 2022 Hanmi Pharmaceuticals completes a phase I trials in Hypercholesterolaemia (In volunteers) in South Korea (PO) (NCT04762407)